Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13781666 | 1.00 | EPHX2 (0.46) | EPHX2SMN1; SMN2ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL13781667 | 1.00 | EPHX2 (0.46) | EPHX2SMN1; SMN2ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL1104706 | 0.88 | EPHX2 (0.53) | EPHX2SMN1; SMN2CYP2D6KCNH2HRH3 | |
| SCHEMBL12384517 | 0.88 | EPHX2 (0.53) | EPHX2SMN1; SMN2CYP2D6KCNH2HRH3 | |
| SCHEMBL25018493 | 0.88 | EPHX2 (0.57) | EPHX2SMN1; SMN2ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL14904406 | 0.87 | EPHX2 (0.38) | EPHX2SMN1; SMN2ALDH1A1MAPK1HTR2A | |
| SCHEMBL13225910 | 0.85 | EPHX2 (0.58) | EPHX2SMN1; SMN2ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL21340435 | 0.85 | CYP2D6 (0.38) | EPHX2SMN1; SMN2ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL24777816 | 0.85 | CYP2D6 (0.38) | EPHX2SMN1; SMN2ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL28240876 | 0.85 | CYP2D6 (0.38) | EPHX2SMN1; SMN2ALDH1A1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-06-23 | — | — | US | disclosed |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | EPHX2 533/4885SMN1; SMN2 4547/4885ALDH1A1 947/4885 |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | EPHX2 327/4885SMN1; SMN2 2352/4885ALDH1A1 684/4885 |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | EPHX2 1845/4885SMN1; SMN2 3910/4885ALDH1A1 3337/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EPHX2 327/4885SMN1; SMN2 2352/4885ALDH1A1 684/4885 |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | EPHX2 3267/4885SMN1; SMN2 2247/4885ALDH1A1 2855/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | EPHX2 1704/4885SMN1; SMN2 4194/4885ALDH1A1 2583/4885 |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | KRAS, NRAS, RB1 | EPHX2 2417/4885SMN1; SMN2 2190/4885ALDH1A1 959/4885 |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | EPHX2 647/4885SMN1; SMN2 970/4885ALDH1A1 1402/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | EPHX2 2689/4885SMN1; SMN2 1569/4885ALDH1A1 1744/4885 |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | EPHX2 3471/4885SMN1; SMN2 2762/4885ALDH1A1 2186/4885 |
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN2, ERN1 | EPHX2 1576/4885SMN1; SMN2 88/4885ALDH1A1 2541/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | EPHX2 669/4885SMN1; SMN2 4086/4885ALDH1A1 1168/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | EPHX2 3568/4885SMN1; SMN2 4578/4885ALDH1A1 4459/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | EPHX2 1580/4885SMN1; SMN2 152/4885ALDH1A1 2438/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | EPHX2 3267/4885SMN1; SMN2 2247/4885ALDH1A1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.